Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $762.00 to $834. ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Intech Investment Management LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT – Free Report) by 41.1% during the fourth quarter, according to the company in its most recent 13F filing with ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other blue chip stocks to invest in at 52-week lows. For the first time since ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed last Friday at $2.98. Discover the latest stocks ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.